Growing prevalence of the target disease is anticipated to be the key driver for Narcolepsy Therapeutics Industry growth. According to the estimates by the Narcolepsy Network, approximately 1 in 2,000 people in the U.S. suffer from the target disease. Steep increase in the incidence rates of the disease was observed in several countries of Europe after H1N1 vaccination program in 2009, which led to rise in awareness about this rare disorder.
Furthermore, patient awareness programs conducted by various organizations, such as Narcolepsy Network Inc., European Narcolepsy Network, Wake Up Narcolepsy, American Sleep Association, Narcolepsy Canada, and Narcolepsy UK accelerate the number of diagnoses and treatment, and drive industry growth. Presence of favorable reimbursement policies for FDA-approved prescription medicines such as Xyrem further boosts the market growth.
Browse Detail Report With TOC @ http://www.hexareports.com/report/narcolepsy-therapeutics-market/details
Further key findings from the study suggest:
Narcolepsy without cataplexy is estimated to be the fastest growing segment of market with a CAGR of over 12% during the forecast period. Key factor attributing for the market growth includes rising number of awareness campaigns conducted by various narcolepsy networks, which are expected to increase the number of diagnoses and treatment over the forecast period.
Sodium Oxybate dominated the overall industry in 2014, with market share of over 78%. Xyrem is the only FDA-approved drug specially indicated for usage in cataplexy and EDS associated with narcolepsy from this category. Presence of favorable reimbursement policies, high prices associated with this drug, and the rising awareness levels pertaining to the disease are few factors responsible for the large share of this segment.
CNS stimulants are considered to be the first line of treatment for various sleep disorders such as ADHD, obstructive sleep apnea, and work shift disorder. However, they are estimated to lose market share over the forecast period owing to patent expiration of key drugs in this category such as Provigil and Nuvigil.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/105542
Europe is estimated to be the largest region of the industry. It dominated the market in terms of revenue with USD 375.23 million in 2014, owing to better patient and practitioner awareness levels about this rare disorder and presence of favorable government initiatives pertaining to its research and development.
Asia Pacific is expected to witness significant growth with a CAGR of around 13% over the forecast period owing to emerging economies in this region, rising investments in pharmaceutical and biotechnology sector, supportive government initiatives, and rapidly growing healthcare industry. Moreover, prevalence rates in Japan are reported to be the highest as compared to the other major countries of the world.
Browse All Pharmaceutical Market Research Related Reports @ http://www.hexareports.com/category/pharmaceutical-market
Major players operating in the market include Teva Pharmaceutical Industries Ltd., Addrenex Pharmaceuticals, Jazz Pharmaceuticals Plc, Arena Pharmaceuticals, Ligand Pharmaceuticals, Graymark Healthcare Inc., Shire Plc, and BIOPROJET
Industry participants are constantly engaged in spreading awareness about this rare disease amongst the physicians and the patients. Strategic alliances and licensing deals amongst the major players of the industry further drive industry growth.
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe.We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Our Website: http://www.hexareports.com
Company Name: Hexa Reports
Contact Person: Ryan Shaw
Address:Felton Office Plaza, 6265 Highway 9
Country: United States